Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syntara Limited ( (AU:SNT) ) has shared an announcement.
Syntara Limited will host an investor webinar on 3 February 2026, led by CEO Gary Phillips and Non-Executive Director Hashan De Silva, to outline its 2026 company outlook and detail progress across its extensive clinical pipeline. The session, which will include a live Q&A and a replay option, comes as the company prepares for five key clinical data readouts during 2026, underscoring a pivotal year for its development programs and providing shareholders and potential investors with greater visibility on upcoming milestones and the potential value inflection points in its oncology, fibrosis and neuroinflammation portfolios.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited (ASX: SNT) is a Sydney-based, clinical-stage drug development company focused on targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry and related technologies. Its pipeline includes lead candidate amsulostat for myelofibrosis and myelodysplastic syndrome, topical pan-LOX inhibitors SNT-9465 and SNT-6302 for hypertrophic and keloid scars, and SNT-4728 for sleep disorders and neurodegenerative diseases such as Parkinson’s, alongside other candidates for fibrotic and inflammatory conditions affecting organs such as the kidney, liver, lungs and heart. The company, which previously developed and sold respiratory products Bronchitol and Aridol, is listed on the ASX under code SNT and concentrates on blood cancers, inflammation and fibrosis-related diseases.
Average Trading Volume: 1,297,173
Technical Sentiment Signal: Sell
Current Market Cap: A$58.77M
See more data about SNT stock on TipRanks’ Stock Analysis page.